聚焦超声增强血脑屏障通透性治疗脑肿瘤:临床试验的系统综述
该系统综述检索PubMed与ClinicalTrials.gov至2023年11月,纳入35项研究(11项已发表研究、24项正在进行试验),评估聚焦超声联合微泡开放血脑屏障以优化脑肿瘤药物治疗的临床证据,认为该策略有前景,但需药代动力学研究定量评估药物摄取改善,且多数为I期试验,需长期随访评估临床获益。
要点
- 聚焦超声联合微泡可安全、精准、非侵入性开放血脑屏障并增强药物摄取。
- 纳入35项研究,以胶质瘤(含胶质母细胞瘤和星形细胞瘤)为主,仅1篇涉及乳腺癌脑转移。
- 儿童人群证据有限,无已发表研究,仅3项正在进行试验。
核心结论
- 聚焦超声是安全开放血脑屏障、精准非侵入性靶向病灶并增强药物递送的有前景策略。
- 需药代动力学研究定量评估药物摄取改善。
- 多数研究为I期临床试验,需长期随访评估患者结局以评价临床获益。
研究设计与样本
- 系统综述,检索PubMed与ClinicalTrials.gov至2023年11月,检索词为「ultrasound」AND「brain tumor」。
- 检索获1446条结果,经标题和摘要筛选及全文筛选(n=48)后,35项研究纳入分析。
- 纳入分析包括11项已发表研究和24项正在进行试验。
主要发现
- 研究主要聚焦胶质瘤,包括胶质母细胞瘤(GBM)和星形细胞瘤。
- 1篇论文研究乳腺癌脑转移。
- 证据表明聚焦超声促进血脑屏障开放并增强超声辐照后药物摄取。
- 儿童人群探索有限,无已发表研究,仅3项正在进行试验专门针对该人群。
临床怎么用
- 原文未据此给出推荐。
局限性
- 儿童人群探索有限,无已发表研究,仅3项正在进行试验专门针对该人群。
- 需药代动力学研究定量评估药物摄取改善。
- 多数研究为I期临床试验,需长期随访评估患者结局以评价临床获益。
- 需纳入多样人群和病理类型的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Brain tumors, particularly glioblastoma multiforme (GBM), present significant prognostic challenges despite multimodal therapies, including surgical resection, chemotherapy, and radiotherapy. One major obstacle is the limited drug delivery across the blood-brain barrier (BBB). Focused ultrasound (FUS) combined with systemically administered microbubbles has emerged as a non-invasive, targeted, and reversible approach to transiently open the BBB, thus enhancing drug delivery. This review examines clinical trials employing BBB opening techniques to optimise pharmacotherapy for brain tumors, evaluates current challenges, and proposes directions for further research. METHODS: A systematic literature search was conducted in PubMed and ClinicalTrials.gov up to November 2023, searching for "ultrasound" AND "brain tumor". The search yielded 1446 results. After screening by title and abstract, followed by full-text screening (n = 48), 35 studies were included in the analysis. RESULTS: Our analysis includes data from 11 published studies and 24 ongoing trials. The predominant focus of these studies is on glioma, including GMB and astrocytoma. One paper investigated brain metastasis from breast cancer. Evidence indicates that FUS facilitates BBB opening and enhances drug uptake following sonication. Exploration of FUS in the pediatric population is limited, with no published studies and only three ongoing trials dedicated to this demographic. CONCLUSION: FUS is a promising strategy to safely disrupt the BBB, enabling precise and non-invasive lesion targeting, and enhance drug delivery. However, pharmacokinetic studies are required to quantitatively assess improvements in drug uptake. Most studies are phase I clinical trials, and long-term follow-up investigating patient outcomes is essential to evaluate the clinical benefit of this treatment approach. Further studies involving diverse populations and pathologies will be beneficial.
引用
- Zhu H, Allwin C, Bassous MG, et al. Focused ultrasound-mediated enhancement of blood-brain barrier permeability for brain tumor treatment: a systematic review of clinical trials. J Neurooncol. 2024. PMID: 39207625. doi:10.1007/s11060-024-04795-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。